Latest revenue
$1.6M
as of 2026-03-31
Latest net income
$-7.7M
as of 2026-03-31
Net margin
-496.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $10.4M
- Enterprise value
- $10.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.56
- 52-wk low
- $0.07
- Beta
- —
- Shares out
- 125.7M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
ITEM 1. BUSINESS Overview Incorporated in 2022, we are a holding company for existing and future planned operating companies centered around pharmaceuticals and healthcare services. We seek to be a micro health ecosystem, with a portfolio of companies consisting of a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, we intend to shift the dynamic of pharmaceutical care…
AI summary unavailable — showing raw filing excerpt
Generated from WGRX's filing dated 2026-03-20
Key risks
ITEM 1A. RISK FACTORS Summary Risk Factors Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “Risk Factors” and should be carefully considered, together with other information in this Annual Report and our other filings with the SEC, before making an investment decision regarding our securities. ● Our limited operating history as a combined company and our evolving business make it difficult to evaluate our current business and future…
AI summary unavailable — showing raw filing excerpt
Generated from WGRX's filing dated 2026-03-20
Profitability
Gross margin
-27.5%
382.5%Operating margin
-401.7%
1085.1%Net margin
-433.9%
1047.4%Return on equity
813.6%
899.1%Return on assets
-332.5%
2680.3%Leverage
Debt / equity
-3.45×
145.9%Long-term debt / equity
-1.01×
159.8%Debt / assets
140.9%
59.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.6M | -85.6% | $-7.7M | +76.1% | -496.5% |
Q4 2025 2025-12-31 | $1.7M | — | $-27.9M | -543.0% | -1667.2% |
Q3 2025 2025-09-30 | $3.0M | -46.9% | $-34.3M | -1738.1% | -1139.0% |
Q2 2025 2025-06-30 | $7.8M | +17391.8% | $-6.7M | -1061.8% | -85.6% |
Q1 2025 2025-03-31 | $10.9M | — | $-32.4M | -38916.0% | -298.5% |
Q4 2024 2024-12-31 | — | — | $-4.3M | — | — |
Q3 2024 2024-09-30 | $5.7M | — | $-1.9M | — | -32.9% |
Q2 2024 2024-06-30 | $44.5K | — | $-574.3K | — | -1289.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122
Your notes
Keep private notes on WGRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns WGRX
Institutional value
$104.4K
Total shares held
1.1M
Distinct holders
6
-13 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 604.2K | $58.0K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 309.6K | $29.7K | — | New |
| 3 | JANE STREET GROUP, LLC | 94.0K | $9.1K | +52.2K (+124.8%) | Added |
| 4 | ACT Advisors, LLC. | 35.4K | $3.4K | — | New |
| 5 | VALLEY FORGE INVESTMENT CONSULTANTS INC ADV | 23.0K | $2.2K | +0 (+0.0%) | No change |
| 6 | Sentinus, LLC | 20.3K | $2.0K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once WGRX's latest filing finishes processing.